Search Results for: PDGFRA

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel ERBB3 erb-b2 receptor tyrosine kinase 3
  • Tucatinib
  • Type I diabetes mellitus
  • Lethal congenital contractural syndrome (LCCS)
Novel FBXO25 F-box protein 25
Novel FZR1 fizzy and cell division cycle 20 related 1
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • SCF-beta-TrCP mediated degradation of Emi1
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
  • Regulation of APC/C activators between G1/S and early anaphase
  • Phosphorylation of Emi1
  • Senescence-Associated Secretory Phenotype (SASP)
  • Assembly of the pre-replicative complex
  • CDK-mediated phosphorylation and removal of Cdc6
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • Transcriptional Regulation by VENTX
  • Aberrant regulation of mitotic exit in cancer due to RB1 defects
  • Antigen processing: Ubiquitination & Proteasome degradation
Novel GRB14 growth factor receptor bound protein 14
  • Tie2 Signaling
Novel GRM1 glutamate metabotropic receptor 1
  • G alpha (q) signalling events
  • Class C/3 (Metabotropic glutamate/pheromone receptors)
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Sensory perception of sweet, bitter, and umami (glutamate) taste
  • Glutamic acid
  • (S)-alpha-methyl-4-carboxyphenylglycine
Novel HGF hepatocyte growth factor
  • Platelet degranulation
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • MET Receptor Activation
  • Negative regulation of MET activity
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates RAS signaling
  • MET activates PI3K/AKT signaling
  • MET activates PTPN11
  • MET activates PTK2 signaling
  • MET interacts with TNS proteins
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • MET activates STAT3
  • Drug-mediated inhibition of MET activation
  • Valproic acid
  • Heparin
  • O2-Sulfo-Glucuronic Acid
  • N,O6-Disulfo-Glucosamine
  • ABT-510
  • Foretinib
Novel ITGAV integrin subunit alpha V
  • Cross-presentation of particulate exogenous antigens (phagosomes)
  • Elastic fibre formation
  • PECAM1 interactions
  • Molecules associated with elastic fibres
  • Integrin cell surface interactions
  • Integrin cell surface interactions
  • TGF-beta receptor signaling activates SMADs
  • Laminin interactions
  • Syndecan interactions
  • Syndecan interactions
  • ECM proteoglycans
  • VEGFA-VEGFR2 Pathway
  • Signal transduction by L1
  • Neutrophil degranulation
  • Mechanical load activates signaling by PIEZO1 and integrins in osteocytes
  • Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
  • Antithymocyte immunoglobulin (rabbit)
  • Levothyroxine
  • PLN-74809
Novel ITGB3 integrin subunit beta 3
  • Platelet degranulation
  • Elastic fibre formation
  • PECAM1 interactions
  • Molecules associated with elastic fibres
  • Integrin cell surface interactions
  • Integrin cell surface interactions
  • TGF-beta receptor signaling activates SMADs
  • Syndecan interactions
  • Syndecan interactions
  • ECM proteoglycans
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • VEGFA-VEGFR2 Pathway
  • Signal transduction by L1
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Mechanical load activates signaling by PIEZO1 and integrins in osteocytes
  • Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
  • Abciximab
  • Eptifibatide
  • Antithymocyte immunoglobulin (rabbit)
  • Levothyroxine
  • Tirofiban
  • Resveratrol
  • Lefradafiban
  • LM-609
  • Fradafiban
  • Ferric maltol
  • Allograft rejection
  • Glanzmann thrombasthenia
Novel JAK1 Janus kinase 1
  • Interleukin-6 signaling
  • Interleukin-6 signaling
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • ISG15 antiviral mechanism
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Other interleukin signaling
  • RAF/MAP kinase cascade
  • Interleukin-10 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • IL-6-type cytokine receptor ligand interactions
  • Interferon gamma signaling
  • Regulation of IFNG signaling
  • Regulation of IFNG signaling
  • Interleukin-20 family signaling
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Interleukin-35 Signalling
  • Interleukin-9 signaling
  • Interleukin-2 signaling
  • Interleukin-12 signaling
  • Interleukin-12 signaling
  • Interleukin-27 signaling
  • Interleukin-27 signaling
  • Interleukin-21 signaling
  • Interferon alpha/beta signaling
  • Interleukin receptor SHC signaling
  • Regulation of IFNA/IFNB signaling
  • Regulation of IFNA/IFNB signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Potential therapeutics for SARS
  • Inactivation of CSF3 (G-CSF) signaling
  • Inactivation of CSF3 (G-CSF) signaling
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • IFNG signaling activates MAPKs
  • Evasion by RSV of host interferon responses
  • PD-L1(CD274) glycosylation and translocation to plasma membrane
  • Myricetin
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • Ruxolitinib
  • Tofacitinib
  • Baricitinib
  • Fostamatinib
  • Fedratinib
  • Filgotinib
  • Abrocitinib
  • Upadacitinib
  • Pralsetinib
  • Ivarmacitinib
Novel KASH5 KASH domain containing 5
Novel KDELR2 KDEL endoplasmic reticulum protein retention receptor 2
  • COPI-mediated anterograde transport
  • COPI-dependent Golgi-to-ER retrograde traffic
Novel LATS2 large tumor suppressor kinase 2
  • Signaling by Hippo
Novel MAP2K5 mitogen-activated protein kinase kinase 5
  • Signalling to ERK5
  • Fostamatinib
  • Pimasertib
Novel MYC MYC proto-oncogene, bHLH transcription factor
  • Transcription of E2F targets under negative control by DREAM complex
  • Signaling by ALK
  • NOTCH1 Intracellular Domain Regulates Transcription
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • MAPK6/MAPK4 signaling
  • Ub-specific processing proteases
  • Interleukin-4 and Interleukin-13 signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • TFAP2 (AP-2) family regulates transcription of cell cycle factors
  • RUNX3 regulates WNT signaling
  • Estrogen-dependent gene expression
  • Transcriptional regulation of granulopoiesis
  • Regulation of CDH1 mRNA translation by microRNAs
  • Regulation of NFE2L2 gene expression
  • Regulation of PD-L1(CD274) transcription
  • Acetylsalicylic acid
  • Dimethyl sulfoxide
  • Doconexent
  • Nadroparin
  • Penile cancer
  • Breast cancer
  • Laryngeal cancer
  • Oral cancer
  • Multiple myeloma
  • Kaposi's sarcoma
  • Ovarian cancer
  • Choriocarcinoma
  • Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
  • Burkitt lymphoma
  • Small cell lung cancer
  • Osteosarcoma
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
Novel NF2 NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor
  • Regulation of actin dynamics for phagocytic cup formation
  • RHO GTPases activate PAKs
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Malignant pleural mesothelioma
Novel NHERF1 NHERF family PDZ scaffold protein 1
  • Nephrolithiasis/osteoporosis, hypophosphatemic
Novel PDGFA platelet derived growth factor subunit A
  • Non-integrin membrane-ECM interactions
  • NFE2L2 regulating tumorigenic genes
  • Glioma
  • Malignant pleural mesothelioma
Novel PDGFB platelet derived growth factor subunit B
  • Platelet degranulation
  • PIP3 activates AKT signaling
  • Downstream signal transduction
  • Signaling by PDGF
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Non-integrin membrane-ECM interactions
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Pegpleranib
  • Glioma
  • Malignant pleural mesothelioma
Novel PDGFC platelet derived growth factor C
Novel PDGFRB platelet derived growth factor receptor beta
  • PIP3 activates AKT signaling
  • Downstream signal transduction
  • Signaling by PDGF
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Becaplermin
  • Sorafenib
  • Imatinib
  • Dasatinib
  • Sunitinib
  • XL999
  • XL820
  • Pazopanib
  • Midostaurin
  • Regorafenib
  • Nintedanib
  • Polaprezinc
  • Trapidil
  • Foreskin fibroblast (neonatal)
  • Tivozanib
  • Fostamatinib
  • Erdafitinib
  • Pexidartinib
  • Ripretinib
  • Pralsetinib
  • Glioma

Page 2 out of 7 pages